Viking Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -87 | -75 | -74 | |
EBITDA | -46,128 | -36,556 | -34,054 | -33,999 |
EBIT | -46,238 | -36,643 | -34,129 | -34,073 |
Net Income | -35,417 | -24,940 | -22,250 | -27,356 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -31,181 | -21,962 | -28,513 | -6,134 |
Cash | 26,676 | 50,347 | 43,915 | 195,579 |
Basic Shares | 109,973 | 110,910 | 110,390 | 103,457 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $10 |
Gross Profit | -292 | -291 | -296 | |
EBITDA | -150,921 | -100,827 | -70,355 | -55,393 |
EBIT | -100,827 | -70,646 | -55,689 | |
Net Income | -109,963 | -85,895 | -67,379 | -54,002 |
Net Change In Cash | 0 | 0 | 0 | 10 |
Cost of Revenue | 10,519 | -2,746 | ||
Free Cash Flow | -87,790 | -73,376 | -48,397 | -47,586 |
Cash | 26,676 | 55,516 | 36,632 | 26,371 |
Basic Shares | 109,037 | 94,347 | 76,834 | 77,197 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.32 |
2024-09-30 | -$0.22 |
2024-06-30 | -$0.20 |
2024-03-31 | -$0.26 |
